Category: Sectors

Categories
Shares Small Cap

Nitro Software expects attractive growth runway

Investment Thesis

  • Sizeable market opportunity of US$28bn TAM (company estimates which is based on ground up model taking into account customer contract values).
  • Established a solid foundation to build from – the Company has penetrated 68% of the Fortune 500 companies and whilst initial involvement with these companies may be small however it provides opportunity to scale up with these customers (approx. 10% of the Fortunes 500 customers have 100 or more licensed users).  
  • Structural tailwinds – ongoing migration to online with businesses looking to digitize manual, paper driven processes.
  • Looking to become a platform.
  • Attractive recurring revenue base via subscriptions. 
  • Investment in R&D to continue developing the Company’s competitive position and enhance value proposition with customers.   

Key Risks 

  • Rising competitive pressures, especially the larger players like Adobe Inc and DocuSign
  • Growth disappoints the market, given the company trades on high valuation multiples – growth in subscriptions, new customers and penetration of existing clients. 
  • Product innovation stalls and fails to resonate with customers. 
  • Emergence of new competitors and technology.

Bulls Say’s

  • Revenue excluding Connective of US$50.7m, was up +26%, and at the top end of the upgraded guidance range. Revenue including Connective was US$50.9m. Annual Recurring Revenue (‘ARR’) excluding Connective was US$40.1m, up +41% and in line with guidance (reaffirmed in October 2021 of US$39m – US$42m). ARR including Connective was US$46.2m, up +62%.
  • Operating EBITDA loss excluding Connective was US$7.4m, and including Connective was US$7.6m, in line with the upgraded guidance range of US$7.5m – US$8.0m provided by the Company in January 2022, and significantly lower than the guidance range of US$11m – US$13m provided at the beginning of FY2021.
  • NTO exceeded 1m active subscription PDF licences, reaching 1.1m at FY21-end.
  • NTO executed 2.2m Nitro Sign eSignature requests excluding Connective eSignatures, up +102%, and more than 22m eSignature requests including Connective.
  • NTO completed a A$140.0m capital raise and hence NTO retains a strong balance sheet with no debt and cash and cash equivalents of US$48.2m including Connective.

Company Profile 

Nitro Software Ltd (NTO), founded in 2005 & listed in 2019, is a global document productivity software company. NTO offers integrated PDF productivity, eSignature and business intelligence (BI) tools through a horizontal SaaS and desktop-based software suite. The Company helps customers move to 100% digital document workflows, eliminating paper and accelerating business processes. NTO serves customers around the world and counts 68% of the Fortune 500 companies among its customers. In total, NTO has over 12,000 business customers (who are defined as having at least 10 licensed users) and across 155 countries.  

(Source: BanyanTree)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

Ford Is Focusing Its People Better by Separating the Combustion and Electric Vehicle Businesses

Business Strategy and Outlook

Ford is also focused on spending on the most profitable vehicles and the March 2022 split of combustion and BEV into their own segments (Ford Blue and Ford Model e) allows talent to focus on combustion hits like Bronco and F-Series as well as build on the success of the F-150 Lightning BEV and Mustang Mach-E. Restructuring in foreign markets is underway and as of year-end 2021, Ford projects up to $2.4 billion of EBIT charges in 2022, bringing total costs for its Global Redesign program to about $11 billion since 2018. Up to about $7 billion of cash may be spent to fund the restructuring, which includes downsizing in markets like Europe and Brazil, but all but about $1 billion of this cash will be spent across 2018-22. Ford Blue seeks about $3 billion in cost reductions.

Ford is building more models on common platforms, which should improve economies of scale. In 2007, Ford had 27 platforms but now has five flexible architectures across unibody, body on frame, and battery electric vehicles. This move allows Ford to switch production faster to meet changing demand while cutting costs via better economies of scale. In the past, Ford had a different platform in each segment for each part of the world, which wasted billions. Lincoln also entered China in fall 2014 and the Mustang Mach-E EV is bringing new customers in U.S. coastal markets, with 70% of its early buyers new to Ford. The F-150 Lightning BEV pickup has over 75% of its reservation holders new to Ford and it and the Transit BEV are on sale in 2022.

Financial Strength

Year-end 2021 global pension underfunding totaled only about $326 million compared with about $8.2 billion at year-end 2015, while salaried employee retiree healthcare added another $6 billion of shortfall. The entire pension underfunding is from pay-as-you-go plans (mostly from Germany and U.S. senior management plans) that are always unfunded and pay benefits paid from general corporate cash. Management guides funded plan contributions to be limited to annual service cost. 2022 contributions are guided at $600 million to $800 million, plus $390 million of benefits for unfunded plans. Unfunded plan benefit payments will likely be around $300 million to $400 million annually.

Automotive debt excluding legacy obligations at year-end 2021 was $20.4 billion, down from $34.4 billion at the end of 2009, but Ford did issue $8 billion in bonds in April 2020 to deal with the coronavirus fallout and we like that Ford redeemed $7.6 billion of expensive bond debt for $9.3 billion in December 2021. At the end of 2021, Ford had available automotive liquidity of $41.8 billion, excluding its 12% stake in Rivian, with $25.9 billion of that amount in cash and securities. In September 2021, Ford amended its credit lines to have a $10.1 billion line through September 2026, a $3.4 billion line in September 2024, and a $2 billion supplemental line also in September 2024. The lines have their rate partially tied to ESG metrics around the environment.

Bulls Say’s

  • Ford’s turnaround will take lots of time due to many restructuring projects around the world but so far the international business seems to be getting better. 
  • Ford is focusing its investments where it gets the best return, which is why mostly exiting North American car segments and production in South America, is the right move, in our opinion. 
  • Ford has tried to remove some administrative layers, and we like CEO Farley’s aggressive moves into electric vehicles, something Ford had been slow to do in the past.

Company Profile 

Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022 the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor Company. The company has about 12.5% market share in the United States, about 6.5% share in Europe, and about 2.4% share in China including unconsolidated affiliates. We expect market share increases as inventory improves coming out of the chip shortage. Sales in the U.S. made up about 64% of 2021 total company revenue. Ford has about 183,000 employees, including about 56,000 UAW employees, and is based in Dearborn, Michigan.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

PointsBet Holdings Ltd (PBH) reported 1H22 reflecting mixed results – on a statutory basis, revenue of $139.1m is up +85%

Sydney, Australia - March 14, 2013: The Australia Stock Exchange big board viewed from the sidewalk in front of the exchange building in Sydney. The ASX board displays real-time stock information for companies listed on the exchange.

Investment Thesis:

  • U.S. growth opportunity – the U.S. online sports betting market continues to open following the 2018 supreme court ruling which legalizes the industry. Market growth estimates forecast the industry to grow to US$51bn by 2033.
  • Strong management team with a solid track record – the ability to grow market share in a competitive and mature market of Australia gives us some confidence the management team has the right strategy in place to build share in the U.S. 
  • Proprietary technology stack – The speed and useability are key differentiating factors. PBH operates proprietary technology, which it developed inhouse. This means new modifications and updates are easier to implement (i.e., more control) with inhouse tech versus outsourced.
  • Cross sell opportunities with iGaming – PBH’s recently launched iGaming product (online casino) is already highlighting cross-sell opportunities to its customers.

Key Risks:

  • Rising competitive pressures.
  • Adverse regulatory change in key operating jurisdictions (Australia / U.S.).
  • Loss of market share in key regions or growth rate fails to meet market expectations.
  • Higher than expected costs – especially around investment in sales & marketing to drive market share.
  • Trading on high PE-multiples / valuations means the Company is more prone to share price volatility. 
  • Cyber-attack on PBH’s platform.
  • Deeply discounted capital raising. 

Key Highlights:

  • PointsBet Holdings Ltd (PBH) reported 1H22 reflecting mixed results – on a statutory basis, revenue of $139.1m is up +85%, driven by Australia Trading and U.S Trading. EBITDA loss of -$130.6m, is -83% weaker than the pcp, with Australia Trading seeing a loss of -$16.1m versus $8.0m in the pcp.
  • On a normalised basis, net revenue of $139.1, and gross profit of $54.7m, are significant increases from $75.1m and $54.7m, in the pcp. Operating expenses increased to $180.8m, up from $95.1m in 1H21. EBITDA loss of $126.0m is significantly weaker than the loss of $69.0m in 1H21.
  • Australia continues to go from strength to strength. Canada is on the verge of an exciting hard launch, which will leverage our global capabilities with a brilliant local strategy and the U.S. is now gaining scale being live in 10 states.  As it relates to North America, PointsBet has positioned itself as an indispensable significant player in the market.
  • The operators that own their technology and can execute a national strategy will be the operators that can maximize profit margins and maximize the huge North American opportunity”. The rating is given as buy because PBH offers attractive risk reward at these levels.

Company Description:

PointsBet Holdings Ltd (PBH), founded in 2015, is a corporate bookmaker with operations in Australia and the United States (New Jersey, Iowa, Illinois and Indiana). PointsBet has developed a scalable cloud-based wagering platform which offers customers sports and racing wagering products. PBH’s key products include fixed odds sports, fixed odds racing and PointsBetting. 

(Source: Banyantree)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Global stocks

Cochlear Limited’s net profit was up +26% to $158m, driven by strong sales growth & improved gross margin.

Investment Thesis:

  • Attractive market dynamics – growing population requiring hearing aids, improving health in EM providing more access to devices such as hearing aids and relatively underpenetrated market. There remains a significant, unmet and addressable clinical need for cochlear and acoustic implants that is expected to continue to underpin the long‐term sustainable growth of COH. 
  • Market leading positions globally.
  • Direct-to-consumer marketing expected to fast track market growth.
  • Best in class R&D program (significant dollar amount) leading to continual development of new products and upgrades to existing suite of products.
  • New product launches driving continued demand in all segments.
  • Attractive exposure to growth in China, India and more recently Japan.
  • Solid balance sheet position.
  • Potential benefit from Australian tax incentive. Subject to successful passage of legislation, the patent box tax regime for medical technology and biotechnology should encourage development of innovation in Australia by taxing corporate income derived from patents at a concessional effective corporate tax rate of 17%, with the concession applying from income years starting on or after 1 July 2022.

Key Risks:

  • Product recall.
  • Sustained coronavirus outbreak which delays recommencement of hospital operations in China.
  • R&D program fails to deliver innovative products.
  • Increase in competitive pressures.
  • Change in government reimbursement policy.
  • Adverse movements in AUD/USD.
  • Emerging market does not recoup – significant downside to earnings. 

Key Highlights:

  • Revenue increased +12% to $815m driven by demand for sound processor upgrades and new acoustic implant products, despite Cochlear implant revenue continuing to be impacted by Covid‐related restrictions which caused lower overall operating theatre capacity. Cochlear implant units increased +7% to 18,598.
  • Statutory net profit of $169m includes $12m in innovation fund gains after‐tax. Underlying net profit was up +26% to $158m, driven by strong sales growth and improved gross margin, with some benefit from lower‐than‐expected operating expenses.
  • The Board declared an interim dividend of $1.55 per share, up +35% and equates to a payout of 65% of underlying net profit (up from 61% in the pcp). Management expects dividend payout to be around 70% for the full year, in line with our target payout.
  • COH’s balance sheet remains strong with net cash of $506m and operating cash flows sufficient to fund investing activities and capex.
  • Cochlear implant units increased +7% to 18,598 units, driven by strong growth in emerging markets (up +30%), offsetting a decline in developed markets (down -2%). Revenue was up +2% to $457.9m, with a mix shift to the emerging markets.
  • For the emerging markets, unit volumes overall increased around +30% with a strong recovery from Covid‐related surgery deferrals experienced across most countries. Surgeries in a few countries, including China, are trading above pre‐Covid levels. India and Brazil are recovering well although volumes are still materially below pre‐Covid levels.
  • In service segment revenue increased +21% to $256.5m, driven by a growing recipient base. Sound processor upgrade revenue saw a strong growth due to pent-up demand following the restricted access to clinics during Covid lockdowns.
  • In acoustics segment Revenue increased +40% to a record $100.9m, reflecting strong demand for new products and a recovery from Covid‐related surgery delays.

Company Description:

Cochlear Ltd (COH) researches, develops and markets cochlear implant systems for hearing impaired people. COH’s hearing implant systems include Nucleus and Baha and are sold globally. COH has direct operations in 20 countries and 2,800 employees. 

(Source: Banyantree)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Global stocks Shares

QBE FY21 statutory NPAT improve to $750m, as premiums shot up by an average of 9.7% during the year

Sydney, Australia - March 14, 2013: The Australia Stock Exchange big board viewed from the sidewalk in front of the exchange building in Sydney. The ASX board displays real-time stock information for companies listed on the exchange.

Investment Thesis 

  • New CEO announced could bring a fresh perspective and potential rebasing of earnings. 
  • As a global insurer, QBE’s operations are much more diversified than domestic peers which means insurance risk is more spread out. 
  • Solid global reinsurance program should insulate earnings from catastrophe claims.
  • Expected prolonged period of lower interest rates (which does not benefit QBE’s investment portfolio).
  • Committed to the share buyback program.
  • Undertook a simplification process and sold non-core operations.

Key Risks

  • New CEO announced could bring a fresh perspective and potential rebasing of earnings. 
  • As a global insurer, QBE’s operations are much more diversified than domestic peers which means insurance risk is more spread out. 
  • Solid global reinsurance program should insulate earnings from catastrophe claims.
  • Expected prolonged period of lower interest rates (which does not benefit QBE’s investment portfolio).
  • Committed to the share buyback program.
  • Undertook a simplification process and sold non-core operations.

1H22 Results Highlights                

Relative to the pcp:   

  • Statutory NPAT improved to $750m from a loss of $1,517m in pcp, reflecting a material turnaround in underwriting profitability. Adjusted net cash profit after tax improved to $805m from a loss of $863m in pcp and equated to ROE of 10.3%. 
  •  GWP grew +22% to $18,457m reflecting the strong premium rate environment (average group-wide rate increases averaged +9.7%) as well as improved customer retention and new business growth across all regions with growth in Crop exceptionally strong at 51% due to the significant increase in corn and soybean prices coupled with targeted organic growth. Excluding Crop, GWP increased +18%, or +10% in excess of premium rate increases, up +600bps over pcp, including growth in excess of rate of +15%, +7% and +11% in North America, International and Australia Pacific, respectively. 
  • Combined operating ratio improved -10.5% over pcp to 93.7% as pcp was significantly impacted by Covid-19 claims and adverse prior accident year claims development. North America Crop business reported a combined operating ratio of 92.7%, declining -550bps over pcp. 
  •  Statutory expense ratio declined -140bps over pcp to 13.6% amid operational efficiencies, remaining on track to reach 13% by 2023. 
  • Catastrophe claims were $905M (6.6% of net earned premium vs 5.8% in pcp), up +31.5% over pcp and 90bps above the Group’s increased allowance. 
  • Investment income declined -46% over pcp to $122m amid negative mark-to-market impact of higher risk-free rates on fixed income portfolio. 
  •  Capital position strengthened with indicative pro-forma APRA PCA multiple increasing +0.03x to 1.75x, at the higher end of 1.6–1.8x target range and pro-forma gearing (debt/capital) declining -170bps to 24.1%, within the 15–30% target range. 
  •  Probability of adequacy (PoA) of net outstanding claims reduced -80bps to 91.7% but remained towards the top end of our 87.5–92.5% target range. 

Company Profile

QBE Insurance Group Ltd (QBE) is a global general insurer that underwrites commercial and personal policies across North America, Australia and New Zealand, Europe and emerging markets. QBE’s Equator Re segment is its captive reinsurer, providing reinsurance protection to the entire Group’s operating divisions.

 (Source: Banyantree)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Global stocks Shares

Cost Absorption Normalizes as Top Line Growth Moderates at No-Moat Wayfair

Business Strategy and Outlook

Wayfair continues to take share in the fragmented home goods market. The firm’s differentiation comes by way of product breadth and its logistics network, which permits faster delivery of both small and large parcels than most of its peers. Targeting a wide consumer base with a customer aged 20-64 years old (200 million domestic households) with income of $25,000-$250,000 also means Wayfair is competing with mass-market retailers, specialty retail, and low-cost providers, making it harder to stay top of mind. This, along with no switching costs, underlies our no-moat rating.

Wayfair’s inventory-light model benefits inventory turns, a strategy has freed up capital to spend on customer acquisition and retention, leading to 27 million active users as of December 2021 who spend around $500 per year (versus 1.3 million users who spent $300 in 2012). This implies its product mix and marketing are resonating with end users. The pandemic pulled forward the capture of positive free cash flow to 2020, and scale should allow Wayfair to generate positive free cash flow to equity over our forecast, even with constraints from infrastructure spend in Europe and IT investment.

Given Wayfair’s lifecycle position, with significant growth potential but also corresponding expenses to achieve market share gains, we expect ROICs to be volatile. We think Wayfair can hit some of its long-term goals, but the duration of execution to achievement is trickier. While it should exceed its prior 25%-27% gross margin target longer term (we forecast reaching 29% due to higher private label mix), we don’t see operating expenses in management’s targeted range 15%-19% of sales until beyond 2031. We plan to watch post pandemic customer acquisition cost trends to determine whether Wayfair could develop a network effect.

Financial Strength 

Wayfair carries modest levels of debt, keeping its financial profile stable as it grows into a more mature business. It carried about $3 billion in long-term debt at competitive rates on its balance sheet as of Dec. 30, 2021, after executing a $535 million convertible raise in April 2020 and another $1.5 billion convertible raise in August 2020. The firm also has access to liquidity through its $600 million credit facility, which matures in 2026. There is cash and marketable securities ($2.4 billion at the end of December) to help cover expenses like operating lease obligations.Over the past two fiscal years, the company has turned free cash flow positive (CFO minus capital expenditures plus site and software development costs). Free cash flow has averaged about 1% of revenue during the past five years, a metric that should average a mid-single-digit rate over the next decade benefiting from increasing scale. Capital expenditures have averaged 2% of sales over the last five years, which we consider a reasonable run rate as the brand invests back into the business to further support top line growth and improving profitability. Morningstar analysts don’t expect the board to initiate a dividend in the near term, given the volatile cash flow pattern that Wayfair has generated in recent years and the need for the firm to continue to invest heavily in technology and customer acquisition. However, in August 2021 it authorized a $1 billion share buyback program, which we would expect to at least partially be deployed in 2022 after shares declined nearly 16% during calendar 2021.

Bull Says

  • Different brands in the Wayfair portfolio cater across income and age demographics, offering some resiliency in cases of macroeconomic cyclicality and economic uncertainty. 
  • Over the last five years, the company has expanded into untapped markets such as Canada, the United Kingdom, and Germany. Additionally, international opportunities could provide location and revenue growth and improved brand awareness. 
  • B2B represents around 10% of sales and targets a $200 billion total addressable market in the U.S. and Europe. This opportunity could grow materially faster than we anticipate.

Company Profile

Wayfair engages in e-commerce in the United States and Europe. At the end of 2021, the firm offered more than 33 million products from 23,000-plus suppliers for the home sector under the brands Wayfair, Joss & Main, AllModern, DwellStudio, Birch Lane, and Perigold. This includes a selection of furniture, decor, decorative accent, housewares, seasonal decor, and other home goods. Wayfair was founded in 2002 and is focused on helping people find the perfect product at the right price.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Small Cap

Invocare ltd operating revenue was up 11% to $527.1m with acquisitions executed in 2H20 contributing $26.7m

Investment Thesis

  • Trades in-line with our blended valuation (DCF / PE-multiple). IVC is currently trading on a 12-mth blended forward PE-multiple of 30.0x and 2.4% dividend yield. 
  • IVC continues to be impacted by Covid-19 and associated lockdown/containment measures.
  • Potential for increased death rates.
  • Continued cost control from strategic review and operational efficiency.
  • IVC benefits from demographics and long-term population growth.
  • IVC holds leading market positions in its core markets.
  • IVC has strong cash flow conversion and generation.
  • High barrier to entry with quality assets and a business model that is difficult to replicate.  
  • Increased competition from budget operators in Australia.

Key Risks

  • Continued reduction in death rate compared to expectations/forecasted trend.
  • Increased competition especially around pricing.
  • Protect and Grow 2020 does not yield incremental returns as anticipated.
  • Underperformance of funds under management.

FY21 Results Highlights

  • Statutory Revenue of $532.5m, up +11%.
  • Operating Revenue up +11% to $527.1m.
  • Operating EBITDA up +22% to $125.5m, with a return to positive operating leverage.
  • Operating EBIT up +36% to $77.8m.
  • Reported Profit After Tax of $80.2m, was higher than the loss of $11.5m in the pcp.
  • IVC achieved strong cashflow conversion of 105%, ROCE of 11.2% and leverage ratio of 1.2x.
  • Operating EPS of 31.6 cents, up 51% on pcp.
  • The Board declared a final fully franked dividend of 11.5cps which takes Full Year dividends to 21.0cps (equating to 66% dividend payout ratio).
  • IVC maintained a strong balance sheet with net debt at $144m at year-end, representing a leverage of 1.2x, a slight improvement on the pcp.  

Company Profile 

InvoCare Ltd (IVC) is the largest private funeral, cemetery and cremation operator in the Asia Pacific Region. It has leading market positions in countries like Australia, New Zealand, and Singapore. 

(Source: BanyanTree)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

Box Is Successfully Targeting a Niche in the Enterprise Content Management Space

Business Strategy and Outlook

Box has sought to differentiate its offerings using a two-step strategy. First, the company has pivoted away from cloud storage, an area where price competition can be fierce, especially for smaller players such as Box. Instead, the firm has focused on redesigning its platform as a collaboration ecosystem. With features such as Box Sign, Relay, and Governance, the firm is creating an open garden where users can interact with native Box features, along with more than 1,500 integrations from various software vendors, to manage their daily workflows. 

First, some other key competitors in the enterprise collaboration space include the likes of Microsoft and Google. These players have access to significantly more capital than Box, creating a tough competitive environment. Second, the legacy solutions that businesses often use for collaboration or document sharing are well entrenched, leading to high switching costs for businesses adopting Box’s solution.

Financial Strength

Box’s financial health to be in good shape. Although the company remains unprofitable in GAAP terms, we are encouraged by the firm’s positive free cash flow, or FCF, which we expect to trend upward as the firm is able to trim operating costs while maintaining solid top-line growth. The firm’s balance sheet is also in good shape, with cash and equivalents well above $500 million at the end of fiscal 2022. While Box has long-term debt, we do not foresee the firm encountering any difficulties in paying its obligations via its strong cash reserves and forecast FCF generation. With a strong net cash balance and cash flow generation profile, it is expected that management to pursue further M&A coupled with continued share repurchases. Management has been active on both of these fronts recently with tuck-in acquisitions of SignRequest and Cloud FastPath and significant share repurchase programs.

Fourth-quarter revenue of $233 million, buoyed by product stickiness and larger deal wins, was up 17% year over year. Much like other software-as-a-service companies, Box can grow its revenue in two ways: increasing average revenue per user, or ARPU, and/or increasing its number of paid users. Box has increased its ARPU by upselling its product to existing clients and increasing large deal sizes, with $100,000-plus deals growing 25% year over year. Management provided revenue guidance between $233 million and $235 million for the first quarter in fiscal year 2023, with adjusted EPS between negative $0.05 and negative $0.04. Full-year guidance was $990 million to $996 million for revenue with adjusted EPS landing between negative $0.07 and negative $0.03.

Bulls Say’s

  • Box’s revenue is buoyed by secular tailwinds as enterprise workflow collaboration tools remain in hot demand. 
  • With the firm’s focus on the enterprise space, clients are typically sticky, leading to more certainty around revenue. 
  • Box’s large install base and go-to-market motion will allow the firm to drive top-line growth while also enacting operating efficiencies leading to better free cash flow generation.

Company Profile 

Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Dividend Stocks

Magellan Financial Group posted strong result; Announced bonus issue and share buyback

Investment Thesis

  • Principal Investments could grow to become a meaningful contributor to group performance over the medium-to-long term. 
  • MFG no longer trades at a significant premium to its peer-group post the recent de-rating. 
  • Acquisitions could pave growth runways, helping to ease the Company’s fund capacity constraints.
  • Average base management fee (bps) per annum (excluding performance fee) continues to be stable but there are risks to the downside from pressures on fees (which is an industry trend not specific to MFG alone).
  • Continued strong investment performances, especially in the global and infrastructure funds.
  • Growing levels of funds under management.  
  • New strategies could significantly increase the addressable market and help sustain earnings growth. 

Key Risk

  • Decline in fund performance.
  • Risk of potential funds outflow – both retail and institutional (loss of a large mandate).
  • Execution risk with the acquisitions.
  • Significant key man risk around Hamish Douglass and key management or investment management personnel.
  • New strategies fail to add meaningful earnings to the group. 

1H22 results summary :Compared to pcp: 

  • Adjusted revenue increased +15% to $384.1m, driven by a +13% increase in total management and service fee revenue amid +12% increase in average FUM to $112.7bn and +116% increase in other revenue (includes distribution income of $8.6m, realised capital gains of $8.1m and net FX gain of $2.1m), partially offset by -8% decline in performance fees. 
  •  Adjusted expenses increased +24% to $65.3m with Funds Management business’s cost to income ratio (excluding performance fees) increasing +60bps to 17.4% (excluding earnings contribution from SJP, increased +280bps to 19.6%) and management anticipating Funds Management segment expenses for FY22 to be $125-130m. 
  • Adjusted NPAT of $248.1m increased +16%, and excluding the earnings contribution for the period from the St James’s Place mandate, adjusted NPAT was $212.5m, broadly in line with pcp. 
  •  Strong balance sheet with no debt and total investment assets of $1,016.7m (up +13%) including cash position of $291.5m. 

Capital management

  • Declared a 75% franked interim dividend of 110.1cps, up +13% over pcp and confirmed the dividend policy of 90-95% payout of the profit after tax of the Funds Management business. 
  •  Announced intention to progress with a 1-for-8 bonus issue of options to shareholders and issuance of 10 million unlisted options to staff, both at exercise price of $35 per option and 5-year term (exercisable at any time until expiry). 
  • Taking into consideration the implementation of an on-market share buy-back (subject to various factors including market conditions).  

Company Profile

Magellan Financial Group Ltd (MFG) is a specialist funds management business. MFG’s core subsidiary, Magellan Asset Management Ltd, manages ~$53.6bn of funds under management across its global equities and global listed infrastructure strategies for retail, high net worth and institutional investors. 

(Source: Banyantree)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Global stocks

Jazz Reports Strong Q4, Raising FVE to $172 on Improved Near-Term Outlook; Shares Undervalued

Business Strategy and outlook

Jazz Pharmaceuticals added its leading drug, Xyrem, to its portfolio in 2005 with the acquisition of Orphan Medical for about $123 million. This was a great price for the then newly approved drug, which became a blockbuster. At that point, Xyrem was the only approved treatment for cataplexy (sudden muscle weakness or paralysis) in narcolepsy; it has since garnered additional approvals for excessive daytime sleepiness in patients with narcolepsy. Jazz reached a settlement in 2017 with Hikma Pharmaceuticals to not allow generics on the market until January 2023. Jazz will retain some economic profit from royalties on generic sales and a shared distribution program. 

Management has been focused on diversifying its portfolio, with the new drug approvals of Zepzelca (for metastatic small-cell lung cancer), Rylaze (for acute lymphoblastic leukemia), and Xywav (for the treatment of cataplexy, EDS, and idiopathic hypersomnia). Strong launches and commercialization efforts for these drugs will be crucial for Jazz to diversify its portfolio. Acquiring recently launched drugs has been part of Jazz’s portfolio diversification strategy. In May 2021, Jazz acquired GW Pharmaceuticals for the hefty price of $7.2 billion. GW contributed $677 million to Jazz’s overall 2021 revenue, largely driven by its leading product, Epidiolex. This drug is a cannabidiol for the treatment of severe, rare forms of epilepsy.

Financial Strength

Jazz is in a decent financial position thanks to historically strong cash flow generation from Xyrem’s sales of $7.2 billion. GW’s leading drug, Epidiolex, could be a potential blockbuster grossing over $1 billion annually by 2023. Company has already received FDA approval and is also marketed in Europe. This acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as one year of age. 

The GW acquisition will be dilutive to both GAAP and non-GAAP adjusted net income in the near term, and it will damp adjusted ROICs. Historically, management has pursued both larger deals ($1 billion or more) and smaller, early-stage deals for growth while spending a low-double-digit percentage of sales on R&D. Once the acquisition of GW is fully integrated and management has deleveraged, the company will continue making acquisitions to help expand and diversify its portfolio.

Bulls Say

  • The GW acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as one year of age.
  • Jazz’s extensive network of sleep doctors should give the company a competitive edge when marketing its new sleep therapies.
  • Xyrem’s historically strong cash generation has allowed the company to make recent acquisitions to help diversify its portfolio.

Company Profile

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small-cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.